AMGEN INC. DL-,0001/ US0311621009 /
5/3/2024 9:42:25 PM | Chg. +28.850 | Volume | Bid10:01:53 PM | Ask10:01:53 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
288.100EUR | +11.13% | 16,657 Turnover: 4.89 mill. |
288.600Bid Size: 34 | 290.400Ask Size: 34 | 155 bill.EUR | - | - |
GlobeNewswire
5/2
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Canc...
GlobeNewswire
5/1
Fight Colorectal Cancer Launches ChatCRC: An AI-Powered Chatbot Revolutionizing Colorectal Cancer Su...
GlobeNewswire
5/1
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
4/30
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire
4/24
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti...
GlobeNewswire
4/23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
4/15
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
GlobeNewswire
4/15
Shah Capital nominates two highly qualified independent director candidates for Novavax
GlobeNewswire
4/8
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...